Dr. Ying Huang, CEO of Legend Biotech (LEGN), explains the work his company does on white blood cell cancer. They grew revenue from the drug 84% last quarter to over $500 million, and expect to turn a profit in 2026. He discusses their partnership with Johnson & Johnson (JNJ), international expansion, and the research they’re conducting.